Close Menu

NEW YORK – Mass spectrometry firm 908 Devices on Thursday priced its initial public offering of 6,500,000 shares at $20 per share for anticipated gross proceeds of $130 million.

Shares of the Boston, Massachusetts-based company will begin trading Friday on the Nasdaq under ticker symbol MASS.

908 Devices is also granting the IPO underwriters a 30-day option to purchase up to an additional 975,000 shares of common stock at the IPO price, less the underwriting discounts and commissions.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Researchers are developing a breath test to determine how severe patients' methylmalonic acidemia disease is, FierceBiotech reports.

NPR reports that vaccine developers are working on SARS-CoV-2 vaccines that are easier to store or administer than the current crop.

Reuters reports that France is to recommend that people under 55 who received one dose of AstraZeneca's SARS-CoV-2 vaccine receive a different vaccine for their second dose.